Breaking News, Promotions & Moves

Halia Therapeutics Updates Leadership & Clinical Operations Team

Dr. Margit Janat-Amsbury promoted to Chief Scientific Officer; Tracey Clayton named VP, Program Management & Clinical Operations; Stephen Anthony DO named SVP, Clinical Development.

Author Image

By: Charlie Sternberg

Associate Editor

Halia Therapeutics, a biopharmaceutical company that completed a $30 million Series C financing last year, has announced key leadership additions and promotions. Dr. Margit Janat-Amsbury, Chief Scientific Officer Dr. Margit Janat-Amsbury, MD. PhD. has been promoted to Chief Scientific Officer. In her new role, she will lead Halia’s scientific vision, guiding the discovery and development of innovative therapies that align with the company’s mission to improve patient outcome...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters